

# Joint Working North Cumbria Lipid Optimisation Service

## Executive Summary

**Project title** Optimisation of a multidisciplinary lipid clinic service for better patient experience and outcome

**Project Partners** NHS North Cumbria Integrated Care FT  
AHSN North East & North Cumbria  
Daiichi Sankyo UK Ltd (DSUK)

**Start - Finish date** October 2024 – March 2026

**Project Support** Daiichi Sankyo UK Ltd financial contribution  
£64,609.35.  
Indirect contribution by NHS North Cumbria  
Integrated Care FT and AHSN NENC £62,988.02

This summary has been written by Daiichi Sankyo UK with consultation and approval from the Collaborative/Joint Working Group.

### Project summary

The Blood Sciences department of NHS North Cumbria Integrated Care (NCIC) are proposing a change to the current lipid clinic referral and management pathways in conjunction with North East AHSN. This project aims to implement and optimise a multidisciplinary approach to the management of patients with lipid disorders in the North Cumbria region along with upskilling and education for primary care. This project will create lipid clinic review/screening pathway that begins in Primary Care which will facilitate an integration of secondary and primary care along with reduction in referrals and increasing clinical confidence and experience in lipid management through upskilling of the Primary Care (Practice) workforce.

There are two phases to the project. The first phase will involve AHSN working with 3 PCN's on lipid optimisation and updating the current pathway in line with the AAC lipid management guidance<sup>1</sup> and AAC statin intolerance guidance<sup>2</sup>. The second phase of the project will be to create a lipid clinic review/case finding pathway that begins in Primary Care and establishment of a "Virtual" Consultant-Led multi-disciplinary lipid clinic involving a dietitian and a clinical pharmacist.

## Expected benefits to patients, the NHS & Daiichi-Sankyo

Expected benefits for the Patient:

- Reduction in current waiting list allowing patients faster access to care.
- Ensure timely diagnosis and treatment of hypercholesterolaemia patients
- Dedicated time for patients to be correctly counselled and educated
- Improve patient satisfaction

Expected benefits for NHS:

Projected benefits to Primary Care are:-

- Reduction in the lipid clinic waiting list thereby meeting or exceeding NHS targets for outpatient care.
- Decrease in patients with suboptimal lipid profiles referred to the lipid clinic.
- Reduction in the number of patients with ASCVD not reaching ESC/EAS LDL-C targets.
- Legacy effect of LDL-C management training.

Projected benefits to Secondary Care are:-

- Reduction in lipid clinic patient assessment times.

Expected benefits for Daiichi Sankyo UK

- Better understanding of customers' and patients' needs specific to lipid management in line with local guidelines.
- Greater insight into the practical challenges and workings of delivering a high quality and sustainable lipid service.
- Create more opportunities for the appropriate use of cholesterol lowering drugs in appropriate patients in line with local treatment guidelines.
- Raising the profiles of DSUK as an NHS Partner of choice in improving patient outcomes amongst local and regional stakeholders.

1. [lipid-management-pathway-v7.pdf \(england.nhs.uk\)](#)
2. [statin-intolerance-pathway-v2.pdf \(england.nhs.uk\)](#)